Events & Presentations

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Website by B-to-B Design

Cookie	Duration	Description
cookielawinfo-checkbox-necessary	12 months	This cookie is defined by the GDPR Cookie Consent plugin and records the user’s consent to "Necessary" category cookies.
cookielawinfo-checkbox-performance	12 months	This cookie is defined by the GDPR Cookie Consent plugin. The cookie is used to store the user’s consent to "Performance" category cookies.
pll_language	12 months	The pll _language cookie is used by Polylang to remember the language selected by the user when he comes back to visit again the website. This cookie is also used to get the language information when not available in another way.
viewed_cookie_policy	12 months	This cookie is defined by the GDPR Cookie Consent plugin and is used to store the user’s acceptance or rejection of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	6 months	Records a unique identifier used to generate statistical data on how people use our Website.
_ga_VQ7XH9070S	6 months	Used for reporting and distinguishing a user and to calculate visitor, session and campaign data for site analytics to optimize the services the website can offer.
_gat_gtag_UA_28487651_5	1 minute	Website ID code for tracking visits This cookie is deleted 1 minute after its creation.
_gid	1 day	Records a unique identifier used to generate statistical data on how people use our Website. This cookie is deleted 1 day after its creation.